A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

Part of paid clinical trials in Fort Smith, Arkansas.

Sponsor
Organon and Co
Study ID
NCT05680740
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with intertriginous psoriasis

Key Dates

Start date
Dec 27, 2022
Status verified
Jul 2024
Primary completion
May 18, 2023
Completion
May 25, 2023

Study Design

Enrollment
34 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: VTAMA® (tapinarof) Cream 1%
    VTAMA® (tapinarof) Cream 1% applied topically once daily

Primary Outcome Measure

Percentage of Participants Who Achieve an Intertriginous PGA (iPGA) Score of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement [ Time Frame: from Baseline to Week 12 ]

Locations (7)

FacilityCityStateZIPSite coordinators
Dermavant Investigative SiteFort SmithArkansas72916-
Dermavant Investigative SiteLos AngelesCalifornia90045-
Dermavant Investigative SiteBoca RatonFlorida33431-
Dermavant Investigative SiteMargateFlorida33063-
Dermavant Investigative SitePlainfieldIndiana46168-
Dermavant Investigative SiteHoustonTexas77004-
Dermavant Investigative SiteWebsterTexas77598-

Find similar trials in Fort Smith, AR

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Dermavant Investigative Site· Fort Smith, ARDermavant Investigative Site· Los Angeles, CADermavant Investigative Site· Boca Raton, FLDermavant Investigative Site· Margate, FLDermavant Investigative Site· Plainfield, INDermavant Investigative Site· Houston, TX

Related Studies